Foamix receives FDA approval of Amzeeq topical minocycline treatment for millions of moderate to severe acne sufferers

Foamix Pharmaceuticals

18 October 2019 - Amzeeq is the first ever FDA approved topical form of minocycline.

Foamix Pharmaceuticals a specialty pharmaceutical company, today announced that the U.S. FDA has approved its novel Amzeeq (minocycline) 4% topical foam. 

Amzeeq, formerly known as FMX101, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older and is the first topical minocycline to be approved by the FDA for any condition.

Read Foamix Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US